Navigation Links
Tolerx Announces Achievement of Milestones upon anti-CD4 Antibody Program Advancement and Initiation of Phase 1 Clinical Trial
Date:8/5/2008

CAMBRIDGE, Mass., Aug. 5 /PRNewswire/ -- Tolerx, Inc., a biopharmaceutical company engaged in the discovery and development of novel therapies for the treatment of immune-mediated diseases, announced today that Genentech, a collaborator, has moved a modified version of TRX1, MTRX1011A, an anti-CD4 monoclonal antibody, into a phase 1 clinical trial that has begun enrolling patients. The clinical trial is evaluating the safety and tolerability of both single and multiple doses of MTRX1011A. Under the terms of the collaboration agreement between Tolerx and Genentech, Tolerx realized milestones in the first quarter of this year upon selection of the antibody for further development within Genentech's clinical pipeline and upon IND filing. The initiation of the Phase 1 clinical trial resulted in the realization of an additional milestone by Tolerx.

Dr. Douglas J. Ringler, President and Chief Executive Officer of Tolerx, commented, "We are extremely pleased that our collaboration with Genentech has resulted in the continued advancement of the program, and we look forward to continued progress."

Tolerx and Genentech entered into a collaboration in 2002 to develop and commercialize anti-CD4 monoclonal antibodies. Pursuant to this arrangement, Genentech has the right in all indications to develop, manufacture and commercialize such anti-CD4 monoclonal antibodies. Tolerx will receive additional milestone payments upon further successful development by Genentech of the anti-CD4 monoclonal antibodies in autoimmune or other indications. Tolerx may receive royalties on worldwide net sales of the anti-CD4 monoclonal antibodies that Genentech successfully develops. In lieu of receiving royalties on product sales in the United States, Tolerx has the option to participate in a loss and profit sharing arrangement with Genentech.

About MTRX1011A

MTRX1011A (a modified version of TRX1) is a humanized monoclonal antibody that binds to and down modulates
'/>"/>

SOURCE Tolerx, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Tolerx Advancing Novel Type 1 Diabetes Agent into Phase III Clinical Trial Program Following End of Phase II FDA Meeting
2. Tolerx Achieves Milestone with Completion of Phase Ib Clinical Study of TRX1 in Cutaneous Lupus Erythematosus
3. Medarex Announces Allowance of Investigational New Drug Application for Wholly-Owned Fully Human Anti-PD-L1 Antibody, MDX-1105
4. Cara Therapeutics Announces Successful Completion of Phase I Clinical Trial of Novel Analgesic, CR845
5. MicroDose Technologies Announces Achievement of Phase I Clinical Milestone Triggering First Milestone Payment Under Collaboration with Merck & Co., Inc.
6. Emisphere Announces Recruitment of Novartis Phase III Study for Oral Osteoporosis Treatment
7. Amicus Therapeutics Announces Successful Completion of End of Phase 2 Meeting With FDA for Amigal in Fabry Disease
8. Anpath Group, Inc. Announces Approval of its Disinfectant by the State of Florida
9. Peptimmune Announces Grant of United States Patent for PI-2301 Peptide Copolymer for Multiple Sclerosis
10. Nile Therapeutics Announces Dosing in Second Phase Ib Study of CD-NP in Heart Failure Patients
11. Wound Management Technologies, Inc. Announces Agreement for Evidence Based Study for Diabetic Venous Ulcers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... Dec. 19, 2014  Advanced Medical Isotope Corporation ... engaged primarily in the development of brachytherapy devices ... today announced that a Life Sciences Discovery Fund ... for which AMIC is the commercialization partner.  The ... for the proposal titled "Optimized Injectable Radiogels for ...
(Date:12/19/2014)... N.C. , Dec. 19, 2014 ... optimize a product,s web presence to reflect the ... websites, in particular, must meet the needs of ... and culture. According to recent ... than half of the participating companies averaged more ...
(Date:12/19/2014)... and CARDIFF-BY-THE-SEA, Calif. ... (NASDAQ: SRNE ;  Sorrento), an oncology ... pain, and Conkwest, Inc., a privately-held immuno-oncology company ... Killer (NK) cell-line based therapy, announced today that ... to jointly develop next generation CAR-TNK™ (pronounced as ...
Breaking Medicine Technology:Advanced Medical Isotope Corporation Awarded LSDF Grant As Commercialization Partner 2Advanced Medical Isotope Corporation Awarded LSDF Grant As Commercialization Partner 3Building a Best-in-Class Pharma Global Brand Website 2Sorrento and Conkwest Announce Exclusive Global Collaboration 2Sorrento and Conkwest Announce Exclusive Global Collaboration 3Sorrento and Conkwest Announce Exclusive Global Collaboration 4Sorrento and Conkwest Announce Exclusive Global Collaboration 5
(Date:12/22/2014)... Give a loved one the greatest gift ... and vitality. , For a limited time, HealthiPlus ( ... in special Holiday Wellness gift packages at drastically reduced ... bottle contains cutting-edge, proven nutritional support for joints, mental ... as we age. , Joint Health Plus ...
(Date:12/22/2014)... (PRWEB) December 22, 2014 The MedTech industry ... Inc, a wholly owned subsidiary of PartnerTech AB of Sweden, ... having recently achieved additional ISO Certification. , All signs point ... employment and the likelihood of a repeal of the excise ... . The industry is anticipating annual growth of 9.3% and ...
(Date:12/22/2014)... Xarelto Lawsuit News : Alonso ... has granted a request to centralize pending and subsequent ... Eastern District of Louisiana. The U.S. Judicial Panel On ... to transfer over 50 Xarelto cases–21 lawsuits and 30 ... court for consolidation under U.S. District Judge Eldon E. ...
(Date:12/22/2014)... (PRWEB) December 22, 2014 TheHardwareCity.com now ... glove with many useful features. Customers of the large ... have the new gloves delivered to their home or ... and hand tools that incorporate heavy duty magnets, which ... Glove allows workers to store metal parts on the ...
(Date:12/22/2014)... December 22, 2014 Christmas is days away, ... a fast and easy solution that will please: the ... be purchased from from $25 up to $350," says Kathy ... customer satisfaction and a wide array of skin care products ... and no expiration dates. , Gift delivery past shipping ...
Breaking Medicine News(10 mins):Health News:You Still Have Time to Give the Gift of Health and Vitality to a Mature Loved One 2Health News:PartnerTech Inc. Poised for Growth in MedTech 2Health News:Panel Orders Xarelto Lawsuits Consolidated Into Multi-District Litigation Reports Alonso Krangle LLP 2Health News:Panel Orders Xarelto Lawsuits Consolidated Into Multi-District Litigation Reports Alonso Krangle LLP 3Health News:Panel Orders Xarelto Lawsuits Consolidated Into Multi-District Litigation Reports Alonso Krangle LLP 4Health News:MagnoGrip Pro Utility Magnetic Gloves on Sale at TheHardwareCity.com 2
... time could be counterproductive, researchers say , THURSDAY, Oct. 15 ... and essential part of building an immune response, and ... Tylenol -- after a shot could dampen that response, a ... that a child,s immune system is processing the immunization, providing ...
... Oct. 16 Mars Snackfood US announced today that Kyle Busch, ... Cup Series, plans to go pink this weekend during the NASCAR ... to support Susan G. Komen for the Cure®. Busch plans ... the wheel of an all pink M&M,S car during the Saturday ...
... , FORT WORTH, Texas, Oct. 16 Wound Management ... provider of specialty medical products, announced today that its subsidiary ... 24th Annual Clinical Symposium on Advances in Skin & ... opens on October 22 in San Antonio. , Dr. ...
... ... business, Dr. Philip Straka, a plastic surgeon in Houston , says he’s actually seeing ... ... be hitting a large number of economic sectors, but one area plastic surgeon says its ...
... ... of their "Tats for Tatas" fundraising campaign that will take place throughout ... company,s concerted efforts to raise awareness and funds for Breast Cancer Awareness, ... company will be donating 10% of all proceeds from sales throughout the ...
... to Feature Gena Rowlands , EAST BRUNSWICK, N.J., Oct. 15 ... return home to New Jersey to host a celebrity cocktail ... reception will raise money for National MS Society,s New Jersey ... New Jersey, where it is estimated that almost 10,000 people ...
Cached Medicine News:Health News:Tylenol May Weaken Effectiveness of Kids' Vaccines 2Health News:Mars Lends Sweet Support in Fight Against Breast Cancer Through Its M&M's(R) And Dove(R) Chocolate Brands, as Well as Its Celebrated Race Team 2Health News:Mars Lends Sweet Support in Fight Against Breast Cancer Through Its M&M's(R) And Dove(R) Chocolate Brands, as Well as Its Celebrated Race Team 3Health News:Wound Management Technologies Announces Clinical Study Presentation of CellerateRx(R) Technology at Leading Skin and Wound Care Conference 2Health News:Wound Management Technologies Announces Clinical Study Presentation of CellerateRx(R) Technology at Leading Skin and Wound Care Conference 3Health News:Houston Plastic Surgeon Seeing Growth in Aesthetic Enhancement Procedures Despite Rough Economy 2Health News:Houston Plastic Surgeon Seeing Growth in Aesthetic Enhancement Procedures Despite Rough Economy 3Health News:Atomic Tattoos Announces "Tats for Tatas" October Fundraising Event to Benefit Local Breast Cancer Research 2Health News:East Brunswick Native Returns Home to Help New Jersey Residents Living with MS 2
... high-power, long-pulse Nd:YAG technology provides practitioners with the ... lesions and perform permanent hair reduction on all ... size feature allows the practitioner to instantly switch ... spot size with a simple twist of the ...
...
...
... is your system. CONMED's family of products ... New, state-of-the art generators feature proprietary Energy ... continuous synchronization of current and voltage in ... enables the system to sample current and ...
Medicine Products: